Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

LentiGlobin continues to deliver in latest sickle cell update as bluebird outlines path to accelerated approval, despite patient death

5 years ago

Vertex and CRISPR spotlight another important gene editing advance in a march to a hoped-for cure

5 years ago

Juno, WuXi JV in China score $100M in fresh funding as it sets stage for first CAR-T approval

5 years ago

Sanofi sends a pair of gene therapies back to Oxford Biomedica. Are they salvageable?

5 years ago

Lilly, Incyte-allied Chinese drugmaker Innovent bags Roche as partner in deal that could yield billions

5 years ago

Sarepta reveals positive results in limb-girdle gene therapy trial. What does that mean for DMD?

5 years ago

Add ear gene therapy company Akouos to the ever-growing list of IPOs amid Covid-19

5 years ago

Spark touts animal data for a solution to AAV gene therapy's antibody problem

5 years ago

Early survival data boost Ziopharm's 'controlled IL-12' immunotherapy for glioblastoma

5 years ago

Bob Langer-founded cell therapy player loads up $65M to fund Roche-partnered cancer work while expanding into vaccines for infectious diseases

6 years ago

Rare disease drugmaker Ultragenyx builds case for its gene therapy franchise with fresh trial updates

6 years ago

Pfizer gene therapy ups levels of dystrophin expression in Duchenne trial — but another safety setback mars results

6 years ago

One year on, Capricor's stem cell therapy appears to help DMD patients in small study, but investors balk at the data

6 years ago

Positive pivotal cell graft data bring Novartis-backed Boston biotech step closer to finish line

6 years ago

Vivek Ramaswamy’s brother, Shankar, spins out on his own, launching audacious gene therapy play

6 years ago

Spun out of George Church's lab, this biotech upstart is mapping the AAV universe for Novartis, Sarepta to gaze

6 years ago

FDA isn't lifting the clinical hold on Solid Bio's Duchenne MD gene therapy just yet — but is there a silver lining?

6 years ago

'Deeply committed' Jim Wilson pours more of his life's work into Passage Bio — locking in more gene therapy programs, new tech

6 years ago

BioMarin broadens its gene therapy horizons with a new R&D alliance in rare cardio cases

6 years ago

Novartis spinout resTORbio reverse merges with T cell biotech after big PhIII failure

6 years ago

In the heart of Texas, the AveXis crew gathers for another go at gene therapy with $30M and a powerhouse academic pact to start

6 years ago

Having sold its corporate self, Tocagen auctions off scientific platform to San Diego biotech

6 years ago

Analysis shows Swiss biotech index outshines Nasdaq counterpart, but coronavirus challenges are universal

6 years ago

Merck KGaA adds to gene therapy manufacturing boom with €100M facility in California

6 years ago

First page Previous page 46 47 484950 51 52 Next page Last page